IgA as therapeutic antibody

被引：46

作者：

Leusen, Jeanette H. W. ^{[1
]}

机构：

[1] UMC Utrecht, Immunotherapy Lab, Lab Translat Immunol, Utrecht, Netherlands

来源：

MOLECULAR IMMUNOLOGY | 2015年 / 68卷 / 01期

关键词：

Antibody therapy; IgA; Immunotherapy; FC-ALPHA-RI; IN-VIVO; IMMUNE-RESPONSES; IMMUNOGLOBULIN-A; CD20; ANTIBODIES; RECEPTOR; CD89; CELLS; CYTOTOXICITY; NEUTROPHILS;

D O I：

10.1016/j.molimm.2015.09.005

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

This review is focused on the promises of IgA as a new therapeutic antibody. For more than 30 years IgG molecules have been used in the clinic in the fields of oncology, hematology, auto immune diseases and infections. However, IgA might be a good alternative, since it recruits different effector cells, i.e. polymorphonuclear cells or neutrophils, but can also activate monocytes and macrophages. The present knowledge, but also future direction for IgA-based drugs are discussed. (c) 2015 Elsevier Ltd. All rights reserved.

引用

页码：35 / 39

页数：5

共 35 条

[1] Neutrophils mediate antibody-induced antitumor effects in mice [J].

Albanesi, Marcello ;

Mancardi, David A. ;

Joensson, Friederike ;

Iannascoli, Bruno ;

Fiette, Laurence ;

Di Santo, James P. ;

Lowell, Clifford A. ;

Bruhns, Pierre .

BLOOD, 2013, 122 (18) :3160-3164

[2] Immunoglobulin A A next generation of therapeutic antibodies? [J].

Bakema, Jantine E. ;

van Egmond, Marjolein .

MABS, 2011, 3 (04) :352-361

[3] The shaving reaction: Rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes [J].

Beum, PV ;

Kennedy, AD ;

Williams, ME ;

Lindorfer, MA ;

Taylor, RP .

JOURNAL OF IMMUNOLOGY, 2006, 176 (04) :2600-2609

[4] Serum-free production and purification of chimeric IgA antibodies [J].

Beyer, T. ;

Lohse, S. ;

Berger, S. ;

Peipp, M. ;

Valerius, T. ;

Dechant, M. .

JOURNAL OF IMMUNOLOGICAL METHODS, 2009, 346 (1-2) :26-37

[5]

BOGERS WMJM, 1989, IMMUNOLOGY, V67, P274

[6] IgA EGFR antibodies mediate tumour killing in vivo [J].

Boross, Peter ;

Lohse, Stefan ;

Nederend, Maaike ;

Jansen, Johannes Hendrik Marco ;

van Tetering, Geert ;

Dechant, Michael ;

Peipp, Matthias ;

Royle, Louise ;

Liew, Li Phing ;

Boon, Louis ;

van Rooijen, Nico ;

Bleeker, Wim K. ;

Parren, Paul W. H. I. ;

van de Winkel, Jan G. J. ;

Valerius, Thomas ;

Leusen, Jeanette H. W. .

EMBO MOLECULAR MEDICINE, 2013, 5 (08) :1213-1226

[7]

Boross P, 2012, AM J CANCER RES, V2, P676

[8] Both activating and inhibitory Fc gamma receptors mediate rituximab-induced trogocytosis of CD20 in mice [J].

Boross, Peter ;

Jansen, J. H. Marco ;

Pastula, Agnieszka ;

van der Poel, Cees E. ;

Leusen, Jeanette H. W. .

IMMUNOLOGY LETTERS, 2012, 143 (01) :44-52

[9] The in vivo mechanism of action of CD20 monoclonal antibodies depends on local tumor burden [J].

Boross, Peter ;

Jansen, J. H. Marco ;

de Haij, Simone ;

Beurskens, Frank J. ;

van der Poel, Cees E. ;

Bevaart, Lisette ;

Nederend, Maaike ;

Golay, Josee ;

van de Winkel, Jan G. J. ;

Parren, Paul W. H. I. ;

Leusen, Jeanette H. W. .

HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2011, 96 (12) :1822-1830

[10] Fc receptors are required in passive and active immunity to melanoma [J].

Clynes, R ;

Takechi, Y ;

Moroi, Y ;

Houghton, A ;

Ravetch, JV .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (02) :652-656

← 1 2 3 4 →